181 related articles for article (PubMed ID: 33316942)
1. Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance.
Machado S; Silva A; De Sousa-Coelho AL; Duarte I; Grenho I; Santos B; Mayoral-Varo V; Megias D; Sánchez-Cabo F; Dopazo A; Ferreira BI; Link W
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33316942
[TBL] [Abstract][Full Text] [Related]
2. Screening Health-Promoting Compounds for Their Capacity to Induce the Activity of FOXO3.
Jimenez L; Silva A; Calissi G; Grenho I; Monteiro R; Mayoral-Varo V; Blanco-Aparicio C; Pastor J; Bustos V; Bracher F; Megías D; Ferreira BI; Link W
J Gerontol A Biol Sci Med Sci; 2022 Aug; 77(8):1485-1493. PubMed ID: 34508571
[TBL] [Abstract][Full Text] [Related]
3. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells.
Zanella F; Renner O; García B; Callejas S; Dopazo A; Peregrina S; Carnero A; Link W
Oncogene; 2010 May; 29(20):2973-82. PubMed ID: 20208562
[TBL] [Abstract][Full Text] [Related]
4. Tribbles breaking bad: TRIB2 suppresses FOXO and acts as an oncogenic protein in melanoma.
Link W
Biochem Soc Trans; 2015 Oct; 43(5):1085-8. PubMed ID: 26517928
[TBL] [Abstract][Full Text] [Related]
5. Covalent inhibitors of EGFR family protein kinases induce degradation of human Tribbles 2 (TRIB2) pseudokinase in cancer cells.
Foulkes DM; Byrne DP; Yeung W; Shrestha S; Bailey FP; Ferries S; Eyers CE; Keeshan K; Wells C; Drewry DH; Zuercher WJ; Kannan N; Eyers PA
Sci Signal; 2018 Sep; 11(549):. PubMed ID: 30254057
[TBL] [Abstract][Full Text] [Related]
6. Analysis of human Tribbles 2 (TRIB2) pseudokinase.
Harris JA; Fairweather E; Byrne DP; Eyers PA
Methods Enzymol; 2022; 667():79-99. PubMed ID: 35525562
[TBL] [Abstract][Full Text] [Related]
7. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
8. TRIB2 contributes to cisplatin resistance in small cell lung cancer.
Liang Y; Yu D; Perez-Soler R; Klostergaard J; Zou Y
Oncotarget; 2017 Dec; 8(65):109596-109608. PubMed ID: 29312632
[TBL] [Abstract][Full Text] [Related]
9. The Critical Role of TRIB2 in Cancer and Therapy Resistance.
Mayoral-Varo V; Jiménez L; Link W
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070799
[TBL] [Abstract][Full Text] [Related]
10. Nanobodies identify an activated state of the TRIB2 pseudokinase.
Jamieson SA; Pudjihartono M; Horne CR; Viloria JS; Dunlop JL; McMillan HD; Day RC; Keeshan K; Murphy JM; Mace PD
Structure; 2022 Nov; 30(11):1518-1529.e5. PubMed ID: 36108635
[TBL] [Abstract][Full Text] [Related]
11. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
12. TRIB2 and the ubiquitin proteasome system in cancer.
Salomè M; Campos J; Keeshan K
Biochem Soc Trans; 2015 Oct; 43(5):1089-94. PubMed ID: 26517929
[TBL] [Abstract][Full Text] [Related]
13. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
14. TRIB2-mediated modulation of AMPK promotes hepatic insulin resistance.
Wang D; Kang X; Zhang L; Guo Y; Zhang Z; Ren H; Yuan G
Diabetes; 2024 Feb; ():. PubMed ID: 38394623
[TBL] [Abstract][Full Text] [Related]
15. Anti-Tribbles Pseudokinase 2 (TRIB2)-Immunization Modulates Hypocretin/Orexin Neuronal Functions.
Tanaka S; Honda Y; Honda M; Yamada H; Honda K; Kodama T
Sleep; 2017 Jan; 40(1):. PubMed ID: 28364459
[TBL] [Abstract][Full Text] [Related]
16. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
17. Murine tribbles homolog 2 deficiency affects erythroid progenitor development and confers macrocytic anemia on mice.
Lin KR; Yang-Yen HF; Lien HW; Liao WH; Huang CJ; Lin LI; Li CL; Yen JJ
Sci Rep; 2016 Aug; 6():31444. PubMed ID: 27550848
[TBL] [Abstract][Full Text] [Related]
18. Reciprocal regulation between O-GlcNAcylation and tribbles pseudokinase 2 (TRIB2) maintains transformative phenotypes in liver cancer cells.
Yao B; Xu Y; Wang J; Qiao Y; Zhang Y; Zhang X; Chen Y; Wu Q; Zhao Y; Zhu G; Sun F; Li Z; Yuan H
Cell Signal; 2016 Nov; 28(11):1703-12. PubMed ID: 27515988
[TBL] [Abstract][Full Text] [Related]
19. TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
Ma X; Zhou X; Qu H; Ma Y; Yue Z; Shang W; Wang P; Xie S; Li Y; Sun Y
Oncol Rep; 2018 Apr; 39(4):1910-1918. PubMed ID: 29436678
[TBL] [Abstract][Full Text] [Related]
20. Trib2 expression in granulocyte-monocyte progenitors drives a highly drug resistant acute myeloid leukaemia linked to elevated Bcl2.
O'Connor C; Yalla K; Salomé M; Moka HA; Castañeda EG; Eyers PA; Keeshan K
Oncotarget; 2018 Mar; 9(19):14977-14992. PubMed ID: 29599919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
